

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

International Journal of Infectious Diseases



journal homepage: www.elsevier.com/locate/ijid

Corrigendum

Corrigendum to "Utility of the antigen test for coronavirus disease 2019: factors influencing the prediction of the possibility of disease transmission" [Int J Infect Dis 104 (2021) 65–72]



Kei Yamamoto^{a,*}, Michiyo Suzuki^a, Gen Yamada^a, Tsutomu Sudo^a, Hidetoshi Nomoto^a, Noriko Kinoshita^a, Keiji Nakamura^a, Yoshie Tsujimoto^b, Yusaku Kusaba^b, Chie Morita^b, Ataru Moriya^c, Kenji Maeda^d, Shintaro Yagi^e, Motoi Kimura^f, Norio Ohmagari^a

The authors regret that the following 95% confidence intervals were printed incorrectly in the original version:

Abstract (p. 65)

Error: OR 0.11, 95% confidence interval <u>0.20</u>–0.61 Correct: OR 0.11, 95% confidence interval <u>0.02</u>–0.61

Results (p. 70)

Error: (OR 0.11, 95% CI <u>0.20</u>–0.61) Correct: (OR 0.11, 95% CI <u>0.02</u>–0.61) Supplementary material Table S4 Error: 0.11 (0.20–0.61)

Error: 0.11 (<u>0.20</u>–0.61) Correct: 0.11 (<u>0.02</u>–0.61)

The authors wish to apologise for any inconvenience caused.

^a Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

^b Department of Respirology, National Center for Global Health and Medicine, Tokyo, Japan

^c Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan

^d Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan

e Fujirebio Inc., Tokyo, Japan

^f Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

DOI of original article: http://dx.doi.org/10.1016/j.ijid.2020.12.079

^{*} Corresponding author at: Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.